BEAMTREE HOLDINGS LIMITED (BMT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BMT

BMT - BEAMTREE HOLDINGS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -2.61
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.24

21 Feb
2025

-0.025

OPEN

$0.25

-9.43%

HIGH

$0.25

132,826

LOW

$0.24

TARGET
$0.70 191.7% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
BMT: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.8 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.6 M
Book Value Per Share xxxxxxxxxxxxxxx16.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-0.5 M
Net Profit Margin xxxxxxxxxxxxxxx-18.50 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.82 %
Return on Invested Capital xxxxxxxxxxxxxxx-10.60 %
Return on Assets xxxxxxxxxxxxxxx-8.36 %
Return on Equity xxxxxxxxxxxxxxx-10.82 %
Return on Total Capital xxxxxxxxxxxxxxx-12.56 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx31 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx1.41

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.0 M
Capex % of Sales xxxxxxxxxxxxxxx14.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx4 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

20/02/2025

1

Buy

$0.70

191.67%

Beamtree Holdings provided a first half EBITDA outcome that was better than Shaw and Partners forecast. FY25 annual recurring revenue has been pushed out  with the company reducing guidance for FY25 to growth of 10% versus 20% previously.

Shaw and Partners still expects a strong second half and assesses the outlook into FY26 is well supported, with plenty of catalysts. The Buy, High risk rating is reiterated and the target is steady at 70c.

FORECAST
Shaw and Partners forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.20 cents.
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

24/02/2025

1

Buy

$0.50

108.33%

In Petra Capital's view, Beamtree Holdings' 1H25 result indicated management has been proactively repositioning the cost structure of the business. This resulted in a marginally positive operating profit outcome from a loss y/y and an operating cashflow break-even outcome. 

The step-down in guided FY25 revenue growth forecast to 10% from 20-30% was a disappointment, the broker comments, though this was partly offset by additional disclosure on opportunity pipeline.

The broker cut forecasts on the back of revised guidance. Target price drops to 50c from 56. Buy maintained.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.30 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.
Access Extra Coverage Research History >

BMT STOCK CHART

FNArena News on BMT

1
Australian Broker Call *Extra* Edition – Feb 24, 2025

1:33 PM - Daily Market Reports
2
FNArena Corporate Results Monitor – 22-02-2025

Feb 22 2025 - Australia
3
FNArena Corporate Results Monitor – 20-02-2025

Feb 20 2025 - Australia
4
Australian Broker Call *Extra* Edition – Oct 08, 2024

Oct 08 2024 - Daily Market Reports
5
FNArena Corporate Results Monitor – 06-09-2024

Sep 06 2024 - Australia

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia